Left in Limbo: Dealmakers Predictions for M&A in 2024 bnnbloomberg.ca - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bnnbloomberg.ca Daily Mail and Mail on Sunday newspapers.
Press release content from Business Wire. The AP news staff was not involved in its creation.
AlloVir Research Presented at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
February 11, 2021 GMT
CAMBRIDGE, Mass. (BUSINESS WIRE) Feb 11, 2021
AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, today announced results of a subgroup analysis from a Phase 2, proof-of-concept study (CHARMS) evaluating the company’s lead product candidate, Viralym-M (ALVR105), an allogeneic, off-the-shelf, multi-virus specific investigational T-cell therapy (VST), in allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients with virus-associated hemorrhagic cystitis (V-HC). These data are being presented in an oral presentation during the Transplantation & Cellular Therapy (TCT) Meeting of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR). Additionally, two
Press release content from Business Wire. The AP news staff was not involved in its creation.
AlloVir Announces Data Presentations at the 2021 Transplantation & Cellular Therapy Meeting Digital Experience
January 11, 2021 GMT
CAMBRIDGE, Mass. (BUSINESS WIRE) Jan 11, 2021
AlloVir (Nasdaq: ALVR), a late clinical-stage cell therapy company, announced that it will present three oral presentations and one poster presentation during the Transplantation & Cellular Therapy Meeting of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR) taking place virtually February 8 – 12, 2021.
Details of the oral presentations are as follows:
Assigned session: Oral Abstract - Session C - Health Services